PURPOSE: To evaluate the efficacy, safety, and biocompatibility of a collagen polymer implantable contact lens (ICL) (Staar Collamer) as a posterior chamber phakic intraocular lens (IOL) to correct high @entity1714 . SETTING: Departments of Ophthalmology, Helsinki University Central Hospital, Helsinki, and Tampere University Hospital, Tampere, Finland. METHODS: A Staar Collamer posterior chamber phakic IOL was implanted in 38 eyes of 22 @entity1 with a mean age of 39 years (range 24 to 54 years). The mean preoperative @entity1714 was -15.10 diopters (D) (range -7.75 to -29.00 D). Surgical implantation was performed through a 3.0 mm clear corneal sutureless incision using paraocular anesthesia. The @entity1 were followed clinically up to 3 years. The mean follow-up was 13.6 months (range 6 to 24 months) for refractive data and 22.3 months (range 6 to 35 months) for complications. The possible inflammatory response to the ICL was measured using a laser flare meter in 12 eyes. RESULTS: Postoperatively, all eyes had a significant increase in uncorrected visual acuity, allowing all but 3 @entity1 (5 eyes) to manage most activities without spectacles. The mean spherical equivalent refraction at the last examination was -2.00 D +/- 2.48 (SD) (range +0.13 to -13.00 D), within +/-1.00 D of the targeted refraction in 31 eyes (81.6%) and within +/-0.50 D in 27 eyes (71.1%). In eyes in which the preoperative @entity1714 was less than -18.00 D (n = 28), the achieved refraction was within +/-1.00 D of the intended refraction in 27 eyes (96.4%) and within +/-0.50 D in 24 eyes (85.7%). The refraction remained stable with a statistically insignificant change (P >.05) at each interval during the follow-up. The best corrected visual acuity (BCVA) improved by 1 or more lines in 23 of 32 eyes (71.9%) at 1 year. Two eyes (6.3%) lost 1 line of BCVA. Laser flare photometry showed normal aqueous flare values (11.71 +/- 6.61 photon counts/ms) in the 12 eyes measured at least 6 months after ICL implantation. @entity726 requiring surgical intervention occurred in 3 @entity1 (7.9%). One @entity1 (2.6%) developed @entity231 1.5 years after ICL implantation; both ICLs were removed, and the @entity2516 were corrected by lensectomy and implantation of low-power posterior chamber IOLs. One @entity1 (2.6%) showed progression of @entity10691 at 17 months. CONCLUSION: At 1 year, ICL implantation had good visual and refractive results with excellent biocompatibility. Long-term follow-up is required to confirm that significant complications do not occur in most @entity1 over time.

Implantable contact lens for high XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2516 :: ('MESH:D012030', 'Disease') :: ['refractive errors'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity10691 :: ('MESH:D057092', 'Disease') :: ['dry macular degeneration'] @entity726 :: ('MESH:D005901', 'Disease') :: ['Pupillary block glaucoma'] @entity1714 :: ('MESH:D009216', 'Disease') :: ['myopia']
@entity1714 :: (MESH:D009216,Disease) :: ['myopia']
